Can Bayer’s New Menopause Drug Spark a Turnaround?

The pharmaceutical giant from Leverkusen has achieved a significant regulatory victory during a period when the company continues to grapple with substantial legacy challenges. European approval for its non-hormonal menopause treatment, Lynkuet, arrives as the corporation’s stock seeks positive momentum. The critical question remains whether this single achievement can outweigh the multitude of other issues facing the business.

Bayer’s Lynkuet received marketing authorization from the European Union, following closely on the heels of its clearance by the U.S. Food and Drug Administration. This dual regulatory success provides the pharmaceutical behemoth with access to the vast menopause treatment market, where a non-hormonal therapeutic option could address a Read more...